Core Viewpoint - Frontier Biotech (688221.SH) announced a cash management plan for idle funds raised from its initial public offering and a simplified issuance of shares to specific targets, with a total limit not exceeding RMB 800 million, valid for 12 months from the expiration of the previous authorization period on October 14, 2025 [1] Group 1 - The total cash management limit is set at a maximum of RMB 800 million [1] - The usage period for the funds is effective for 12 months starting from the expiration date of the last authorization [1] - The funds can be used in a rolling manner within the specified limit and timeframe [1]

Group 1 - The core viewpoint of the news is that Frontier Biopharmaceuticals has experienced significant stock price fluctuations, with a year-to-date increase of 53.59% but a recent decline of 15.41% over the past five trading days [1] - As of September 9, the stock price of Frontier Biopharmaceuticals was reported at 14.99 yuan per share, with a total market capitalization of 5.615 billion yuan [1] - The company has seen a net outflow of main funds amounting to 3.2891 million yuan, with large orders showing a buy of 26.5552 million yuan and a sell of 27.5182 million yuan [1] Group 2 - Frontier Biopharmaceuticals, established on January 15, 2013, and listed on October 28, 2020, focuses on the research, development, production, and sales of innovative drugs addressing significant unmet clinical needs [2] - The company has one patented anti-HIV drug on the market and two drugs in clinical trials, showcasing its strong capabilities in long-acting peptide drug development [2] - As of June 30, the number of shareholders increased by 5.74% to 12,000, while the average circulating shares per person decreased by 5.43% to 31,095 shares [2] Group 3 - For the first half of 2025, Frontier Biopharmaceuticals reported an operating income of 58.6398 million yuan, reflecting a year-on-year growth of 14.85%, while the net profit attributable to the parent company was -97.3526 million yuan, an increase of 39.33% year-on-year [2]

证券代码：688221 证券简称：前沿生物 前沿生物药业（南京）股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 9 月 1 目录 | 2025 | 年第一次临时股东大会会议须知 3 | | --- | --- | | 2025 | 年第一次临时股东大会会议议程 5 | | 2025 | 年第一次临时股东大会会议议案 7 | | | 议案一：《关于变更部分募集资金投资项目的议案》 7 | 2 四、 会议期间，全体出席人员应以维护股东的合法权益、保证大会的正常秩序和议 事效率为原则，认真履行法定义务，自觉遵守大会纪律，不得侵犯公司和其他股东的合 法权益，不得扰乱股东大会的正常召开秩序。 五、 会议期间，参会人员应注意维护会场秩序，不要随意走动，手机调整为静音状 态，谢绝个人录音、录像及拍照，对干扰会议正常程序、寻衅滋事或侵犯其他股东合法 权益的行为，会议工作人员有权予以制止，并报告有关部门处理。 六、 股东参加股东大会依法享有发言权、质询权等权利。本次会议安排了股东集中 发言和提问的环节，在各项议案审议完成后，股东请举手示意现场发言或提问，经大会 主持人许可方可发言。股东发言或提问应围绕本次 ...

中国经济网北京9月8日讯前沿生物(688221.SH)今日收报15.30元，跌幅3.29%。目前该股处于破发状 态。 前沿生物于2020年10月28日在上交所科创板上市，本次发行股份数量为8,996万股，占本次发行后总股 本的25.01%，全部为公开发行新股，发行价格为20.50元/股，保荐机构(主承销商)为瑞银证券有限责任 公司，保荐代表人为崔健民、严鹏举，联席主承销商为中信证券股份有限公司。 经计算，前沿生物上述两次募资共20.44亿元。 前沿生物2020年首次公开发行发行费用(不含增值税)总额为12,688.99万元，其中，承销及保荐费用为 11,612.51万元。 保荐机构相关公司UBSAG参与本次发行战略配售，获配股票数量为2,926,829股，占本次发行总量的 3.25%，获配金额59,999,994.50元。UBSAG本次跟投获配股票的限售期为24个月，限售期自本次公开发 行的股票在上交所上市之日起开始计算。 前沿生物实际控制人为DONGXIE(谢东)，美国国籍，拥有中国永久居留权。 2022年9月22日，前沿生物发布的以简易程序向特定对象发行股票上市公告书显示，本次发行数量 14,818,65 ...

资金流向方面，该股今日全天主力资金净流出1.13亿元。（数据宝） 前沿生物9月5日龙虎榜 （原标题：前沿生物龙虎榜：营业部净卖出2912.08万元） 9月5日前沿生物(688221)收盘价15.82元，收盘下跌16.34%，全天换手率14.31%，振幅21.62%，成交额 8.71亿元。科创板交易公开信息显示，当日该股因日收盘价跌幅达15%等上榜。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交2.90亿元， 其中，买入成交额为1.30亿 元，卖出成交额为1.59亿元，合计净卖出2912.08万元。具体来看，今日上榜的前五大买入营业部中，有 2家机构专用席位现身，即买二、买三，买入金额分别为2952.36万元、2568.78万元，营业部合计买入 7507.03万元。卖出营业部中，有1家机构专用席位现身，即卖五，卖出金额分别为2055.94万元，营业部 合计卖出1.39亿元。买卖金额相抵，机构专用席位今日净买入该股3465.20万元。 | 买入营业部名称 | 买入 | | --- | --- | | | 金额(万元) | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 3109.4 ...

Company Overview - Frontline Bio (688221.SH) closed at 15.82 yuan, experiencing a decline of 16.34%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares, accounting for 25.01% of the total shares post-issuance, at a price of 20.50 yuan per share [1] - The highest stock price recorded since listing was 35.53 yuan on the first day of trading [1] Fundraising and Financials - The total amount raised from the issuance was 184.418 million yuan, with a net amount of 171.729 million yuan after expenses [1] - The company aimed to raise 200.085 million yuan for various projects, including clinical research for HIV fusion inhibitors and pain relief patches, as well as for marketing network construction and working capital [1] - The total issuance costs (excluding VAT) for the initial public offering were 12.689 million yuan, with underwriting and sponsorship fees amounting to 11.613 million yuan [1] Strategic Participation - UBSAG, the sponsoring institution, participated in the strategic placement of the issuance, acquiring 2,926,829 shares, which is 3.25% of the total issuance, for an amount of approximately 60 million yuan [2] - The lock-up period for the shares acquired by UBSAG is set for 24 months from the date of listing [2] Additional Issuance - On September 22, 2022, Frontline Bio announced a specific issuance of 14,818,653 shares at a price of 13.51 yuan per share, raising a total of approximately 200.200 million yuan [3] - After deducting issuance costs of approximately 4.533 million yuan, the net amount raised was about 195.667 million yuan [3] - The total fundraising from the two issuances amounts to approximately 2.044 billion yuan [4]

Core Viewpoint - The innovative drug concept stocks experienced a decline, with several companies seeing significant drops in their stock prices [1] Group 1: Stock Performance - Shuyou Shen and Qianyan Biology both fell over 10% [1] - Fuyuan Pharmaceutical hit the daily limit down [1] - Baihua Pharmaceutical, Asia-Pacific Pharmaceutical, Wanbangde, Bailitianheng, and Ruizhiyiyuan all dropped over 5% [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 2.93% on September 4, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haijing Pharmaceutical: closed at 21.20, up 9.67% with a trading volume of 55,600 shares [1] - Jiankai Technology: closed at 99.80, up 7.60% with a trading volume of 44,400 shares [1] - Fuyuan Pharmaceutical: closed at 27.13, up 6.98% with a trading volume of 384,900 shares [1] - Conversely, significant decliners included: - Nanjing New Pharmaceutical: closed at 13.27, down 10.82% with a trading volume of 240,800 shares [2] - Maiwei Biotech: closed at 54.22, down 9.59% with a trading volume of 278,800 shares [2] - Yipinhong: closed at 67.27, down 7.58% with a trading volume of 124,800 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.173 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.619 billion yuan [2][3] - The capital flow for specific stocks indicated: - Fuyuan Pharmaceutical had a net inflow of 212 million yuan from institutional investors [3] - Chenshin Pharmaceutical experienced a net inflow of 117 million yuan from institutional investors [3] - Qianyan Biotech had a net inflow of 102 million yuan from institutional investors [3]

Core Viewpoint - Frontier Biotech (688221.SH) reported a revenue of 58.64 million yuan for the first half of 2025, marking a year-on-year increase of 14.85%, but recorded a net loss attributable to shareholders of 97.35 million yuan, an improvement from a loss of 160 million yuan in the same period last year [1] Financial Performance - The company achieved a net cash flow from operating activities of -98.23 million yuan, compared to -89.19 million yuan in the previous year [1] - From 2018 to 2024, the net profit attributable to shareholders was -247 million yuan, -192 million yuan, -231 million yuan, -260 million yuan, -357 million yuan, -329 million yuan, and -201 million yuan respectively [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the same period was -167 million yuan, -202 million yuan, -240 million yuan, -311 million yuan, -399 million yuan, -355 million yuan, and -327 million yuan respectively [1] Initial Public Offering (IPO) Details - Frontier Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, with an issuance of 89.96 million shares at a price of 20.50 yuan per share [1] - The total amount raised from the IPO was 184.42 million yuan, with a net amount of 171.73 million yuan after expenses [2] - The company planned to use the raised funds for various projects, including the clinical development of HIV fusion inhibitors and pain relief patches, as well as for marketing network construction and working capital [2] Subsequent Fundraising - On September 22, 2022, the company issued 14.82 million shares at a price of 13.51 yuan per share, raising a total of approximately 200.20 million yuan, with a net amount of about 195.67 million yuan after deducting issuance costs [3] - The total fundraising from both IPOs amounted to approximately 2.04 billion yuan [4] Ownership Structure - The actual controller of Frontier Biotech is Dong Xie, who holds American nationality and has permanent residency in China [5]

Group 1 - The innovative drug concept stocks are experiencing significant activity, with Jimin Health hitting the daily limit up [1] - JianKai Technology has seen an increase of over 10% [1] - Other companies such as YueKang Pharmaceutical, NuoSiGe, QianYan Bio, XinLiTai, and Chengdu XianDao are also following the upward trend [1]